Insulin degludec
- Generic Name
- Insulin degludec
- Brand Names
- Ryzodeg, Tresiba, Xultophy
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 844439-96-9
- Unique Ingredient Identifier
- 54Q18076QB
- Background
Insulin degludec is an ultra-long-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas that promotes glucose metabolism. ...
- Indication
Insulin degludec is indicated to improve glycemic control in patients 1 year of age and older with diabetes mellitus.
- Associated Conditions
- Diabetes Mellitus, Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
- Associated Therapies
- -
A Research Study of a New Medicine NNC0363-1063 in Healthy Participants and Participants With Type 1 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2024-11-12
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 154
- Registration Number
- NCT06685185
- Locations
- 🇩🇪
Profil Institut für Stoffwechselforschung GmbH, Neuss, Germany
A Clinical Study of GZR33 and GZR101 in Healthy Subjects
- Conditions
- Interventions
- First Posted Date
- 2024-08-16
- Last Posted Date
- 2024-08-16
- Lead Sponsor
- Gan and Lee Pharmaceuticals, USA
- Target Recruit Count
- 28
- Registration Number
- NCT06556641
- Locations
- 🇨🇳
Study Site, Xingtai, Hebei, China
A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GZR4 in Subjects With Type 2 Diabetes
- First Posted Date
- 2024-08-14
- Last Posted Date
- 2024-08-14
- Lead Sponsor
- Gan and Lee Pharmaceuticals, USA
- Target Recruit Count
- 36
- Registration Number
- NCT06553248
- Locations
- 🇨🇳
Gan & Lee Pharmaceuticals Co., Ltd, Beijing, Beijing, China
A Study to Test How a New Long-acting Insulin Works in the Body of Patients With Type 2 Diabetes During Exercise and Prolonged Fasting
- Conditions
- Interventions
- First Posted Date
- 2024-03-01
- Last Posted Date
- 2024-04-02
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 30
- Registration Number
- NCT06288412
- Locations
- 🇦🇹
Medical University of Graz, Graz, Austria
A Study of LY3938577 in Healthy Participants and Participants With Type 1 Diabetes Mellitus (T1DM)
- Conditions
- Interventions
- First Posted Date
- 2024-02-28
- Last Posted Date
- 2024-05-31
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 70
- Registration Number
- NCT06280703
- Locations
- 🇩🇪
Profil Institut für Stoffwechselforschung, Neuss, Nordrhein-Westfalen, Germany
A Trial Comparing the Efficacy and Safety of GZR4 Injection Versus Insulin Degludec in Subjects with Type 2 Diabetes Mellitus
- Conditions
- Interventions
- First Posted Date
- 2024-01-11
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Gan and Lee Pharmaceuticals, USA
- Target Recruit Count
- 179
- Registration Number
- NCT06202079
- Locations
- 🇨🇳
Study Site 01, Tianjin, China
🇨🇳Study Site 02, Beijing, China
🇨🇳Study Site 05, Beijing, China
Insulin Degludec vs Insulin Glargine for Glycemic Control in Critical Illness Hyperglycemia
- Conditions
- Interventions
- First Posted Date
- 2023-12-21
- Last Posted Date
- 2024-08-05
- Lead Sponsor
- Ain Shams University
- Target Recruit Count
- 90
- Registration Number
- NCT06178874
- Locations
- 🇪🇬
Ain shams university, Cairo, Egypt
A Research Study in Saudi Arabia to Understand How the Dose Check App Used With Tresiba Treatment Helps to Control Blood Sugar Level
- Conditions
- Interventions
- First Posted Date
- 2023-12-01
- Last Posted Date
- 2024-07-05
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 175
- Registration Number
- NCT06153537
- Locations
- 🇸🇦
My clinic, Jeddah, Saudi Arabia
🇸🇦Al Hammadi, Riyadh, Saudi Arabia
🇸🇦Almoosa Specialist Hospital, Ihsaa, Saudi Arabia
A Study to Investigate the Safety and Tolerability of LY3938577 in Healthy Participants and Participants With Type 2 Diabetes Mellitus
- Conditions
- Interventions
- First Posted Date
- 2023-11-15
- Last Posted Date
- 2024-07-24
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 66
- Registration Number
- NCT06132126
- Locations
- 🇺🇸
Labcorp CRU, Dallas, Texas, United States
🇺🇸Qps-Mra, Llc, Miami, Florida, United States
🇺🇸CenExel ACT, Anaheim, California, United States
A Study of Insulin Efsitora Alfa (LY3209590) Compared With Insulin Degludec in Participants With Type 1 Diabetes Treated With Multiple Daily Injection Therapy
- Conditions
- Interventions
- First Posted Date
- 2022-07-19
- Last Posted Date
- 2024-07-29
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 692
- Registration Number
- NCT05463744
- Locations
- 🇺🇸
Palm Research Center Tenaya, Las Vegas, Nevada, United States
🇺🇸Biopharma Informatic, LLC, Houston, Texas, United States
🇺🇸Amir A Hassan, MD, PA, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.